Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
02 10월 2023 - 9:58PM
Business Wire
Virpax® Pharmaceuticals, Inc. (“Virpax” or the
“Company”) (NASDAQ: VRPX), a company specializing in developing
non-addictive products for pain management, post-traumatic stress
disorder, central nervous system (CNS) disorders and viral barrier
indications, announced today that Gerald W. Bruce has been
appointed as President and CEO of Novvae™ Pharmaceuticals, Virpax’s
wholly-owned subsidiary focused solely on advancing the Company’s
OTC pipeline.
Mr. Bruce has spent over 30 years in the pharmaceutical and
medical nutrition industries. Most recently, he served as a Vice
President of sales for Danone Specialized Nutrition North America,
Danone’s medical nutrition division. Prior to this position, he has
held roles of increasing responsibility at Nitromed, Inc. and
Bristol-Meyers Squibb. Mr. Bruce began his career at Johnson and
Johnson and spent 13 years there starting as a sales representative
and moving up the ranks to become a Group Marketing Director in
Analgesics. He has a BA from Lincoln University and an Executive
Master’s Degree in Leadership from Georgetown University’s
McDonough School of Business.
“Gerald, with his background in the pharma and medical nutrition
industries, is uniquely positioned to lead Novvae. His experience
and knowledge of the OTC market will be beneficial to us as we
advance AnQlar™ as well as add new nonprescription product
candidates that will utilize our novel delivery technologies,”
commented Anthony P. Mack, Chairman and CEO of Virpax.
About Novvae Pharmaceuticals
Novvae Pharmaceuticals, a wholly-owned subsidiary of Virpax
Pharmaceuticals, is developing over-the-counter (OTC) products
using innovative metered-dose drug delivery platforms. Novvae is
seeking approval of AnQlar which is being developed to inhibit
viral replication caused by influenza or SARS-CoV-2.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management
products candidates using its proprietary technologies to optimize
and target drug delivery. Virpax is initially seeking FDA approval
for two prescription drug candidates that employ two different
patented drug delivery platforms. Probudur™ is a single injection
liposomal bupivacaine formulation being developed to manage
post-operative pain and Envelta™ is an intranasal molecular
envelope enkephalin formulation being developed to manage acute and
chronic pain, including pain associated with cancer. Virpax is also
using its intranasal Molecular Envelope Technology (MET) to develop
two other product candidates. PES200 is a product candidate being
developed to manage post-traumatic stress disorder (PTSD) and
NobrXiol™ is a product candidate being developed for the nasal
delivery of a pharmaceutical-grade cannabidiol (CBD) for the
management of rare pediatric epilepsy. Virpax recently acquired
global rights to NobrXiol. Virpax has competitive cooperative
research and development agreements (CRADAs) for all three of its
prescription drug candidates, two with the National Institutes of
Health (NIH) and one with the Department of Defense (DOD). Novvae
Pharmaceuticals, a wholly-owned subsidiary of Virpax, is developing
over-the-counter (OTC) products using innovative metered-dose drug
delivery platforms. Novvae is seeking approval of AnQlar which is
being developed to inhibit viral replication caused by influenza or
SARS-CoV-2.For more information, please visit virpaxpharma.com and
follow us on Twitter, LinkedIn and YouTube.
Forward-Looking Statement
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's planned clinical trials, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions and include statements regarding Mr. Bruce being
uniquely positioned to lead Novvae and his experience and knowledge
of the OTC market being beneficial to the Company as it advances
AnQlar as well as adds new nonprescription product candidates that
will utilize its novel delivery technologies. These statements may
be identified by the use of forward-looking expressions, including,
but not limited to, "expect," "anticipate," "intend," "plan,"
"believe," "estimate," "potential,” "predict," "project," "should,"
"would" and similar expressions and the negatives of those terms.
These statements relate to future events or the Company’s financial
performance and involve known and unknown risks, uncertainties, and
other factors, including the contribution of Mr. Bruce, the
Company’s ability to advance AnQlar and add new nonprescription
product candidates that will utilize its delivery technologies, the
Company’s ability to successfully complete research and further
development and commercialization of Company drug candidates in
current or future indications; the uncertainties inherent in
clinical testing; the Company’s ability to manage and successfully
complete clinical trials and the research and development efforts
for multiple product candidates at varying stages of development;
the effects of the outbreak of COVID-19 on the Company’s business
and results of operations; the timing, cost and uncertainty of
obtaining regulatory approvals for the Company’s product
candidates; the Company’s ability to protect its intellectual
property; the loss of any executive officers or key personnel or
consultants; competition; changes in the regulatory landscape or
the imposition of regulations that affect the Company's product
candidates; the Company’s ability to continue to obtain capital to
meet its long-term liquidity needs on acceptable terms, or at all,
including the additional capital which will be necessary to
complete clinical trials that the Company plans to initiate; and
other factors listed under "Risk Factors" in the Company’s annual
report on Form 10-K for the year ended December 31, 2022, the
Company’s quarterly reports on Form 10-Q, Current Reports on Form
8-K and subsequent filings with the U.S. Securities and Exchange
Commission. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002358935/en/
Investor Relations Contact:
Betsy Brod Affinity Growth Advisors Betsy.brod@affinitygrowth.com
(917) 923-8541
Media Contact: Robert Cavosi
RooneyPartners rcavosi@rooneypartners.com (646) 638-9891
Virpax Pharmaceuticals (NASDAQ:VRPX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Virpax Pharmaceuticals (NASDAQ:VRPX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024